Companies in #Oligonucleotide Therapeutics
Found 1 company operating in this sector.
Dyne Therapeutics (NASDAQ: DYN) is a clinical-stage muscle disease company developing targeted therapeutics for genetically driven muscle disorders including Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), and facioscapulohumeral muscular dystrophy (FSHD). Its FORCE platform delivers oligonucleotides to muscle tissue.